## Edgar Filing: ACCELERON PHARMA INC - Form 4

ACCELERO Form 4 May 07, 201	ON PHARMA I	NC									
FORN Check th	<b>4</b> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									PROVAL 3235-0287	
if no lon subject to Section 2 Form 4 of Form 5 obligatio may con <i>See</i> Instr 1(b).	ger o 16. or Filed p nns tinue. Section 1'	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940								January 31, 2005 iverage rs per 0.5	
(Print or Type	Responses)										
Polaris Venture Management Co IV <sub>Symbol</sub>				er Name <b>and</b> Ticker or Trading LERON PHARMA INC N]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				e of Earliest Transaction n/Day/Year) /2014				Director X 10% Owner Officer (give title Other (specify below) below)			
				onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting			
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative S	Securit		Person ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year		ned 1 Date, if	3. Transactio Code (Instr. 8)	4. Securitie our Dispose (Instr. 3, 4	es Acqued of (D and 5) (A) or	uired (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/05/2014			Code V S	Amount 313,491 (1) (2)	(D) D	Price \$ 42.86	2,819,743 <u>(3)</u>	I <u>(3)</u>	See footnote $(3)$	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: ACCELERON PHARMA INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Polaris Venture Management Co IV LLC C/O POLARIS VENTURE PARTNERS 1000 WINTER STREET SUITE 3350 WALTHAM, MA 02451	Х						
POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP C/O POLARIS VENTURE PARTNERS 1000 WINTER STREET SUITE 3350 WALTHAM, MA 02451	Х						
POLARIS VENTURE PARTNERS IV LP C/O POLARIS VENTURE PARTNERS 1000 WINTER STREET SUITE 3350 WALTHAM, MA 02451	Х						
Signatures							
Polaris Venture Management Co. IV, L.L.C., By: /s/ Terrance McGuire	05/06/2014						
**Signature of Reporting Person		Date					
Polaris Venture Partners IV, L.P., By: /s/ Terrance McGuire	05/06/2014						
<u>**</u> Signature of Reporting Person		Date					
Polaris Venture Partners Entrepreneurs Fund IV, L.P., By: /s/ Terrance McGuire							
**Signature of Reporting Person		Date					

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents 307,893 shares and 5,598 shares that were held directly by Polaris Venture Partners IV, L.P. ("PVP IV") and Polaris Venture Partners Entrepreneurs Fund IV, L.P. ("PVPE IV" and, together with PVP IV, the "Funds"), respectively. Polaris Venture Management

(1) Co. IV, L.L.C. ("PVM IV") is the general partner of the Funds. PVM IV disclaims beneficial ownership of these securities and this report shall not be deemed an admission that PVM IV is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest, if any, therein.

(Continued from footnote 1) Each of Jonathan A. Flint, Terrance G. McGuire and Alan G. Spoon are the managing members of PVM IV.
 (2) Each of Messrs. Flint, McGuire and Spoon disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein.

Represents 2,769,495 shares and 50,248 shares that are held directly by PVP IV and PVPE IV, respectively. PVM IV disclaims beneficial ownership of these securities and this report shall not be deemed an admission that PVM IV is the beneficial owner of such securities for

(3) purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest, if any, therein. Each of Jonathan A. Flint, Terrance G. McGuire and Alan G. Spoon are the managing members of PVM IV. Each of Messrs. Flint, McGuire and Spoon disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.